Aromatase: The enzyme and its inhibition

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 627-641

  Banting, Lee ^a   Ahmed, Sabbir ^b  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Aromatase; Enzyme; Heterocyclic; Inhibition; Inhibitor; Mechanism; Natural products

Indexed keywords

16 OXIMINO 5 ANDROSTENE DERIVATIVE; 17 METHYL 16 NITRILE 16,17 SECO 4 ANDROSTENE 3,17 DIONE; 3 DEOXYANDROSTENEDIONE DERIVATIVE; 7ALPHA MERCAPTO DEXTRO HOMO 17 OXAANDROSTA 1,4 DIENE 3,17ALPHA DIONE; AMINOGLUTETHIMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; BENZOFLAVONE; BIOCHANIN A; COUMARIN DERIVATIVE; FLAVAN DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; FORMONONETIN; HESPERETIN; IMIDAZOLE DERIVATIVE; INDOFINE; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; METHYLTESTOSTERONE; MORACHALCONE; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTOESTROGEN; PLANT MEDICINAL PRODUCT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SESQUITERPENE LACTONE DERIVATIVE; TZA 2237; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DENSITY FUNCTIONAL THEORY; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; GENETIC REGULATION; HUMAN; NONHUMAN; POMEGRANATE; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 70349094104     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788680037     Document Type: Article

References (118)

1. Simpson, E.R; Mahendroo, M.S.; Means, G.D.; Kilgore, M.W.; Hinshelwood, M.M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C.R.; Michael, M.D. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15(3), 342-55.
2. Chen, S.; Itoh, T.; Wu, K.; Zhou, D.; Yang, C. Transcriptional regulation of aromatase expression in human breast tissue. J. Steroid. Biochem. Mol. Biol., 2003, 83, 93-99.
3. Howell, A; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 2005, 365(9453), 60-2.
4. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years' Adjuvant Treatment for Breast Cancer. Obstet. Gynecol. Surv., 2005, 60(5), 307-309.
5. Howell, A.; Dowsett, M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res., 2004, 6(6), 269-74.
6. Choueiri, T.K.; Alemany, C.A.; Abou-Jawde, R.M.; Budd, G.T. Role of aromatase inhibitors in the treatment of breast cancer. Clin. Ther., 2004, 26(8), 1199-214.
7. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev., 2005, 26, 331-45.
8. Bulun, S.E.; Sebastian, S.; Takayama, K.; Suzuki, T.; Sasano, H.; Shozu, M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid Biochem. Mol. Biol., 2003, 86, 219-24.
9. Agarwal, V.R.; Ashanullah, C.I.; Simpson, E.R.; Bulun, S.E. Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. J. Clin. Endocrinol. Metab., 1997, 82, 70-4.
10. Rubin, G.L.; Duong, J.H.; Clyne, C.D.; Speed, C.J.; Murata, Y.; Gong, C.; Simpson, E.R. Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology, 2002, 143(8), 2863-71.
11. Fan, W.; Yanase, T.; Morinaga, H.; Mu, Y.M.; Nomura, M.; Okabe, T.; Goto, K.; Harada, N.; Nawata, H. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. Endocrinology, 2005, 146(1), 85-92.
12. Purohit, A.; Ghilchik, M.W.; Leese, M.P.; Potter, B.V.; Reed, M.J. Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues. J. Steroid Biochem. Mol. Biol., 2005, 94(1-3), 167-72.
13. Winnett, G.; van Hagen, D.; Schrey, M. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: potential implications for breast cancer therapy. Int. J. Cancer, 2003, 103(5), 600-5.
14. Andrews, W.J.; Winnett, G.; Rehman, F.; Shanmugasundaram, P.; Hagen, D.; Schrey, M.P. Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J. Steroid Biochem. Mol. Biol., 2005, 94(1-3), 159-65.
15. Perez-Sala, D.; Cernuda-Morollon, E.; Pineda-Molina, E.; Canada, F.J. Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann. N. Y. Acad. Sci., 2002, 973,533-6.
16. Brennan, P.; O'Neill, L.A. Inhibition of nuclear factor kappaB by direct modification in whole cells - mechanism of action of nordi-hydroguaiaritic acid, curcumin and thiol modifiers. Biochem. Pharmacol., 1998, 55(7), 965-73.
17. Baichwal, V.R.; Baeuerle, P.A. Activate NF-kappa B or die? Curr. Biol., 1997, 7(2), R94-6.
18. Giguere V. To ERR in the estrogen pathway. Trends Endocrinol. Metab., 2002, 13, 220-225.
19. Suetsugi, M.; Su, L.; Karlsberg, K.; Yuan, Y.C.; Chen, S. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol. Cancer Res., 2003, 1(13), 981-91.
20. Klinge, C.M.; Kaur, K.; Swanson, H.I. The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. Arch. Biochem. Biophys., 2000, 373(1), 163-74.
21. Fallone, F.; Villard, P.H.; Seree, E.; Rimet, O.; Nguyen, Q.B.; Bourgarel-Rey, V.; Fouchier, F.; Barra, Y.; Durand, A.; Lacarelle, B. Retinoids repress Ah receptor CYP1A1 induction pathway through the SMRT corepressor. Biochem. Biophys. Res. Commun., 2004, 322(2), 551-6.
22. Ghisletti, S.; Meda, C.; Maggi, A.; Vegeto, E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol. Cell. Biol., 2005, 25(8), 2957-68.
23. Gouedard, C.; Barouki, R.; Morel, Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell Biol., 2004, 24(12), 5209-22.
24. Thomsen, J.S.; Kietz, S.; Strom, A.; Gustafsson, J.A. HES-1, a novel target gene for the aryl hydrocarbon receptor. Mol. Pharmacol., 2004, 65(1),165-71.
25. Puga, A.; Tomlinson, C.R.; Xia, Y. Ah receptor signals cross-talk with multiple developmental pathways. Biochem. Pharmacol., 2005, 69(2), 199-207.
26. Lee, J.M.; Anderson, P.C.; Padgitt, J.K.; Hanson, J.M.; Waters, C.M.; Johnson, J.A. Nrf2, not the estrogen receptor, mediates catechol estrogen-induced activation of the antioxidant responsive element. Biochim. Biophys. Acta., 2003, 1629(1-3), 92-101.
27. Brantley, E.; Patel, V.; Stinson, S.F.; Trapani, V.; Hose, C.D.; Ciolino, H.P., Yeh G.C.; Gutkind, J.S.; Sausville, E.A.; Loaiza-Perez, A.I. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. Anticancer Drugs, 2005, 16(2), 137-43.
28. Loaiza-Perez, A.I.; Trapani, V.; Hose, C.; Singh, S.S.; Trepel, J.B.; Stevens, M.F.; Bradshaw, T.D.; Sausville, E.A. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to anti-tumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol. Pharmacol., 2002, 61(1), 13-9.
29. Bradshaw, T.D.; Trapani, V.; Vasselin, D.A.; Westwell, A.D. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr. Pharm. Des., 2002, 8(27), 2475-90.
30. Vanselow, J.; Pohland, R.; Furbass, R. Promoter-2-derived Cyp19 expression in bovine granulosa cells coincides with gene-specific DNA hypo-methylation. Mol. Cell Endocrinol., 2005, 15, 233(1-2), 57-64.
31. Lala, P.; Higashiyama, T.; Erman, M.; Griswold, J.; Wagner, T.; Osawa, Y.; Ghosh, D. Suppression of human cytochrome P450 aromatase activity by monoclonal and recombinant antibody fragments and identification of a stable antigenic complex. J. Steroid Biochem. Mol. Biol., 2004, 88(3), 235-45.
32. Chen, S.; Zhang, F.; Sherman, M.A.; Kijima, I.; Cho, M.; Yuan, Y.C.; Toma, Y.; Osawa, Y.; Zhou, D.; Eng, E.T. Structure-function studies of aromatase and its inhibitors: a progress report. J. Steroid Biochem. Mol. Biol., 2003, 86(3-5), 231-7.
33. Conley, A.; Mapes, S.; Corbin, C.J.; Greger, D.; Walters, K.; Trant, J.; Graham, S. A comparative approach to structure-function studies of mammalian aromatases. J. Steroid Biochem. Mol. Biol., 2001, 79(1-5), 289-97.
34. Auvray, P.; Nativelle, C.; Bureau, R.; Dallemagne, P.; Seralini, G.E.; Sourdaine, P. Study of substrate specificity of human aromatase by site directed mutagenesis. Eur. J. Biochem., 2002, 269(5), 1393-405.
35. Kao, Y.C.; Korzekwa, K.R.; Laughton, C.A.; Chen, S. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur. J. Biochem., 2001, 268(2), 243-51.
36. Conley, A.; Mapes, S.; Corbin, C.J.; Greger, D.; Graham, S. Structural determinants of aromatase cytochrome p450 inhibition in substrate recognition site-1. Mol. Endocrinol., 2002, 16(7), 1456-68.
37. Hackett, J.C.; Brueggemeier, R.W.; Hadad, C.M. The final catalytic step of cytochrome P450 aromatase: A density functional theory study. J. Am. Chem. Soc., 2005, 127(14), 5224-5237.
38. Cavalli, A.; Greco, G.; Novellino, E.; Recanatini, M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors. Bioorg. Med. Chem., 2000, 8(12), 2771-80.
39. Ahmed, S.; Adat, S.; Murrells, A.; Owen, C.P.; Amanuel, Y. Design, synthesis, and evaluation of 4-(4′-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase. Bioorg. Chem., 2002, 30(5), 315-31.
40. Ahmed, S.; Adat, S.; Murrells, A.; Owen, C.P. Novel oxazolidinone based compounds as inhibitors of aromatase and the use of the substrate-heme complex approach in the rationalisation of these compounds. Biochem. Biophys. Res. Commun., 2002, 294(2), 380-3.
41. Numazawa, M.; Yamada, K.; Nitta, S.; Sasaki, C.; Kidokoro, K. Role of hydrophilic interaction in binding of hydroxylated 3-deoxy C(19) steroids to the active site of aromatase. J. Med. Chem., 2001, 44(24), 4277-83.
42. Stresser, D.M.; Turner, S.D.; McNamara, J.; Stocker, P.; Miller, V.P.; Crespi, C.L.; Patten, C.J. A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal. Biochem., 2000, 284(2), 427-30.
43. Almstrup, K.; Fernandez, M.F.; Petersen, J.H.; Olea, N.; Skakkebaek, N.E.; Leffers, H. Dual effects of phytoestrogens result in u-shaped dose-response curves. Environ. Health Perspect., 2002, 10(8), 743-8.
44. Kirk, C.J.; Harris, R.M.; Wood, D.M.; Waring, R.H.; Hughes, P.J. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem. Soc. Trans., 2001, 29, 209-16.
45. Pouget, C.; Fagnere, C.; Basly, J.P.; Besson, A.E.; Champavier, Y.; Habrioux, G.; Chulia, A.J. Synthesis and aromatase inhibitory activity of flavanones. Pharm. Res., 2002, 19(3), 286-91.
46. Vinh, T.K.; Nicholls, P.J.; Kirby, A.J.; Simons C. Evaluation of 7-hydroxy-flavones as inhibitors of oestrone and oestradiol biosynthesis. J. Enzyme Inhib., 2001, 16(5), 417-24.
47. Saarinen, N.; Joshi, S.C.; Ahotupa, M.; Li, X.; Ammala, J.; Makela, S.; Santti, R. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. J. Steroid Biochem. Mol. Biol., 2001, 78(3), 231-9.
48. Bhat, A.S.; Whetstone, J.L.; Brueggemeier, R.W. Novel synthetic routes suitable for constructing benzopyrone combinatorial libraries. Tetrahedron Lett., 1999, 40(13), 2469-2472.
49. Brueggemeier, R.W.; Richards, J.A.; Joomprabutra, S.; Bhat, A.S.; Whetstone, J.L. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J. Steroid Biochem. Mol. Biol., 2001, 79(1-5), 75-84.
50. Brooks, J.D.; Thompson, L.U. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J. Steroid Biochem. Mol. Biol., 2005, 94(5), 461-7.
51. Wang, L.Q. Mammalian phytoestrogens: enterodiol and enterolactone. J. Chromatogr. B., Anal. Technol. Biomed. Life Sci., 2002, 777(1-2), 289-309.
52. Zeligs, M.A.; Jacobs, I.C.: USP 6,086,915, 2000.
53. Taylor, R.B.; Henley, E.C.: USP 6,300,367, 2001.
54. Ahotupa, M.; Eckerman, C.; Kangas, L.; Makela, S.; Saarinen, N.; Santti, R.; Warri, A.: USP 6,451,849, 2002.
55. Chattopadhyay, S.K.; Srivastava, S.; Tripathi, V.: USP 6,372,922, 2002.
56. Kelly, G.E.: USP 6,497,906, 2002.
57. Kelly, G.E.; Husband, A.J.: USP 6,599,536, 2003.
58. Farley, M.D.: USP 6,607,755, 2003.
59. Lee, D.; Bhat, K.P.; Fong, H.H.S.; Farnsworth, N.R.; Pezzuto, J.M.; Kinghorn, A.D. Aromatase inhibitors from Broussonetia papyrifera. J. Nat. Prod., 2001, 64(10), 1286-93.
60. Romano, J.J.; Casillas, E. A short synthesis of morachalcone A. Tetrahedron Lett., 2005, 46, 2323-2326.
61. Dhawan, K. Drug/substance reversal effects of a novel tri-substituted benzoflavone moiety (BZF) isolated from Passiflora incarnata Linn. - a brief perspective. Addict. Biol., 2003, 8(4), 379-86.
62. Dhawan, K.; Dhawan, S.; Sharma, A. Passiflora: a review update. J. Ethnopharmacol., 2004, 94(1), 1-23.
63. Kim, N.D.; Mehta, R.; Yu, W.; Neeman, I.; Livney, T.; Amichay, A.; Poirier, D.; Nicholls, P.; Kirby, A.; Jiang, W.; Mansel, R.; Ramachandran, C.; Rabi, T.; Kaplan, B.; Lansky, E. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res. Treat., 2002, 71(3), 203-17.
64. Eng, E.T.; Ye, J.; Williams, D.; Phung, S.; Moore, R.E.; Young, M.K.; Gruntmanis, U.; Braunstein, G.; Chen, S. Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res., 2003, 63(23), 8516-22.
65. Grube, B.J.; Eng, E.T.; Kao, Y.C.; Kwon, A.; Chen, S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J. Nutr., 2001, 131(12), 3288-93.
66. Papiez, M.; Gancarczyk, M.; Bilinska, B. The compounds from the hollyhock extract (Althaea rosea Cav. var. nigra) affect the aromatization in rat testicular cells in vivo and in vitro. Folia Histochem. Cytobiol., 2002, 40(4), 353-9.
67. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J. Biol. Chem., 2004, 279(46), 48071-8.
68. Blanco, J.G.; Gil, R.R.; Bocco, J.L.; Meragelman, T.L.; Genti-Raimondi, S.; Flury, A. Aromatase inhibition by an 11,13-dihydroderivative of a sesquiterpene lactone. J. Pharmacol. Exp. Ther., 2001, 297(3), 1099-105.
69. Basly, J-P.; Lavier, M.C. Dietary phytoestrogens: potential selective estrogen enzyme modulators? Planta Med., 2005, 71, 287-294.
70. Numazawa, M.; Ando, M.; Zennyoji, R. Studies on the catalytic function of aromatase: aromatization of 6-alkoxy-substituted androgens. J. Steroid Biochem. Mol. Biol., 2002, 82(1), 65-73.
71. Numazawa, M.; Shelangouski, M.; Nagasaka, M. Probing the binding pocket of the active site of aromatase with 6-ether or 6-ester substituted androst-4-ene-3,17-diones and their diene and triene analogs. Steroids, 2000, 65(12), 871-82.
72. Numazawa, M.; Yamada, K.; Nagaoka, M. 19-Oxygenation of C19-steroids with an A, B-ring enone structure, competitive inhibitors of estrogen biosynthesis, with human placental aromatase. Biol. Pharm. Bull., 2001, 24(4), 332-5.
73. Numazawa, M.; Yamada, K.; Watari, Y.; Ando, M. Improved synthesis and molecular modeling of 4beta,19-dihydroxyandrost-5-en-17-one, an excellent inhibitor of aromatase. Chem. Pharm. Bull. (Tokyo), 2002, 50(5), 703-5.
74. Numazawa, M.; Yoshimura, A. Synthesis and biochemical studies of 19-oxygenated derivatives of 6alpha- and 6beta-methylandrostenediones as catalytic probes for the active site of aromatase. Biol. Pharm. Bull., 2000, 23(9), 1059-65.
75. Numazawa, M.; Yoshimura, A.; Watari, Y.; Matsuzaki, H. Aromatase inhibition by 4 beta,5 beta-epoxides of 16 alpha-hydroxyandrostenedione and its 19-oxygenated analogs, potential precursors of estriol production in the feto-placental unit. Biol. Pharm. Bull., 2002, 25(12), 1566-9.
76. Numazawa, M.; Mutsumi, A.; Tachibana, M.; Yoshimura, A. Kinetic analysis of reversible inhibition of 16alpha-hydroxyandrostenedione aromatization in human placental microsomes by suicide substrates of androstenedione aromatization. Biol. Pharm. Bull., 2003, 26(6), 890-2.
77. Numazawa, M.; Yoshimura, A.; Tachibana, M.; Shelangouski, M.; Ishikawa, M. Time-dependent aromatase inactivation by 4 beta,5 beta-epoxides of the natural substrate androstenedione and its 19-oxygenated analogs. Steroids, 2002, 67(3-4), 185-93.
78. Nagaoka, M.; Watari, Y.; Yajima, H.; Tsukioka, K.; Muroi, Y.; Yamada, K.; Numazawa, M. Structure-activity relationships of 3-deoxy androgens as aromatase inhibitors. Synthesis and biochemical studies of 4-substituted 4-ene and 5-ene steroids. Steroids, 2003, 68(6), 533-42.
79. Banting, L. Inhibition of aromatase. Prog. Med. Chem., 1996, 33, 147-84.
80. Numazawa, M.; Watari, Y.; Yamada, K.; Umemura, N.; Handa, W. Probing the active site of aromatase with 2-methyl-substituted androstenedione analogs. Steroids, 2003, 68(6), 503-13.
81. Numazawa, M.; Handa, W.; Yamada, K. Synthesis and biochemical properties of 6-bromoandrostenedione derivatives with a 2,2-dimethyl or 2-methyl group as aromatase inhibitors. Biol. Pharm. Bull., 2004, 27(11), 1878-82.
82. Peet, N.P.; Johnston, J.O.; Burkhart, J.P.: USP 6,313,161, 2001.
83. Droescher, P.; Menzenbach, B.J.; Roemer, W.; Schneider, B.; Elger, W.; Kaufmann, G.: USP 6,436,917, 2002.
84. Ito, K.; Fukabori, Y.; Shibata, Y.; Suzuki, K.; Mieda, M.; Gotanda, K.; Honma, S.; Yamanaka, H. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Eur. J. Endocrinol., 2000, 43(4), 543-54.
85. Penov Gasi, K.M.; Stankovic, S.M.; Csanadi, J.J.; Djurendic, E.A.; Sakac, M.N.; Medic Mijacevic, L.; Arcson, O.N.; Stojanovic, S.Z.; Andric, S.; Molnar Gabor, D.; Kovacevic R. New D-modified androstane derivatives as aromatase inhibitors. Steroids, 2001, 66(8), 645-53.
86. Penov Gasi, K.M.; Miljkovic, D.A.; Medic Mijacevic, L.D.; Djurendic, E.A.; Stojanovic, S.Z.; Sakac, M.N.; Djurendic, M.D.J.; Stankovic, S.M.; Lazar, D.; Andric, S.; Kovacevic, R. Synthesis, X-ray crystal structures and biological activity of 16-amino-17-substituted-D-homo steroid derivatives. Steroids, 2003, 68(7-8), 667-76.
87. Mor, G.; Eliza, M.; Song, J.; Wiita, B.; Chen, S.; Naftolin, F. 17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J. Steroid Biochem. Mol. Biol., 2001, 79 (1-5), 239-46.
88. Baston, E.; Klein, C.D.; Grimminger, W.; Hebecker, N.; Hartmann, R.W. Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type. Anticancer Drug Des., 2001, 16(1), 37-47.
89. Ahmed, S.; Adat, S.; Murrells, A.; Owen, C.P.; Amanuel, Y. Design, synthesis, and evaluation of 4-(4′-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase. Bioorg. Chem., 2002, 30(5), 315-31.
90. Jindal, D.P.; Bedi, V.; Jit, B.; Karkra, N.; Guleria, S. Bansal, R.; Palusczak, A.; Hartmann, R.W. Synthesis and study of some new N-substituted imide derivatives as potential anticancer agents. Farmaco, 2005, 60(4), 283-90.
91. Ahmed, S. The use of the substrate-heme complex approach in the design, synthesis, biochemical evaluation, and rationalization of the inhibitory activity of a range of azole compounds against cholesterol side chain cleavage enzyme. Biochem. Biophys. Res. Commun., 2000, 275(1), 75-6.
92. Jacobs, C.; Frotscher, M.; Dannhardt, G.; Hartmann, R.W. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. J. Med. Chem., 2000, 43(9), 1841-51.
93. Hartmann, R.W.; Wachall, B.; Yoshihama, M.; Nakakoshi, M.; Nomoto, S.; Ikeda, Y.: USP 6,559,157, 2003.
94. Shimada, S.; Nomoto, S.; Okue, M.; Kimura, K.; Nakamura, J.; Ikeda, Y.; Takada, T.: USP 6,689,798, 2004.
95. Vinh, T.K.; Yee, S.W.; Kirby, A.J.; Nicholls, P.J.; Simons, C. 1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase. Anticancer Drug Des., 2001, 16(4-5), 217-25.
96. Karjalainen, A.; Kalapudas, A.; Sodervall, M.; Pelkonen, O.; Lammintausta, R. Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylal-kyltriazole molecule skeletons. Eur. J. Pharm. Sci., 2000, 11(2), 109-31.
97. Recanatini, M.; Bisi, A.; Cavalli, A.; Belluti, F.; Gobbi, S.; Rampa, A.; Valenti, P.; Palzer, M.; Palusczak, A.; Hartmann, R.W. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J. Med. Chem., 2001, 44(5), 672-80.
98. Pouget, C.; Fagnere, C.; Basly, J.P.; Habrioux, G.; Chulia, A.J. Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorg. Med. Chem. Lett., 2002, 12(20), 2859-61.
99. Pouget, C.; Yahiaoui, S.; Fagnere, C.; Habrioux, G.; Chulia, A.J. Synthesis and biological evaluation of 4-imidazolylflavans as non-steroidal aromatase inhibitors. Bioorg. Chem., 2004, 32(6), 494-503.
100. Pouget, C.; Fagnere, C.; Basly, J.P.; Habrioux, G.; Chulia, A.J. New aromatase inhibitors. Synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg. Med. Chem. Lett., 2002, 12(7), 1059-61.
101. Kim, Y-W.; Hackett, J.C.; Brueggemeier, R.W. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem., 2004, 47(16), 4032-4040.
102. Reed, M.J.; Potter, B.V.L.: USP 6,506,792, 2003.
103. Adje, N.; Bonnet, P.; Carniato, D.; Delansorne, R.; Lafay, J.; Pascal, J-C.: USP 6,737,433 B1, 2004.
104. Leze, M.P.; Le Borgne, M.; Marchand, P.; Loquet, D.; Kogler, M.; Le Baut, G.; Palusczak, A.; Hartmann, R.W. 2- and 3-[(aryl) (azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors. J. Enzyme Inhib. Med. Chem., 2004, 19(6), 549-57.
105. Le Borgne, M.; Marchand, P.; Delevoye-Seiller, B.; Robert, J.M.; Le Baut, G.; Hartmann, R.W.; Palzer, M. New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg. Med. Chem. Lett., 1999, 9(3), 333-6.
106. Marchand, P.; Le Borgne, M.; Palzer, M.; Le Baut, G.; Hartmann, R.W. Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(9), 1553-5.
107. Nativelle-Serpentini, C.; Moslemi, S.; Yous, S.; Park, C.H.; Lesieur, D.; Sourdaine, P.; Seralini, G-E. Synthesis and evaluation of benzoxazolinonic imidazoles and derivatives as non-steroidal aromatase inhibitors. J. Enzyme Inhib. Med. Chem., 2004, 19(2), 119-27.
108. Gupta, R.; Jindal, D.P.; Jit, B.; Narang, G.; Palusczak, A.; Hartmann, R.W. Synthesis and evaluation of a dimer of 2-(4-pyridylmethyl)-1-indanone as a novel nonsteroidal aromatase inhibitor. Arch. Pharm. (Weinheim), 2004, 337(7), 398-401.
109. Sonnet, P.; Dallemagne, P.; Guillon, J.; Enguehard, C.; Stiebing, S.; Tanguy, J.; Bureau, R.; Rault, S.; Auvray, P.; Moslemi, S.; Sourdaine, P.; Seralini, G.E. New aromatase inhibitors. Synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. Bioorg. Med. Chem., 2000, 8(5), 945-55.
110. Ulmschneider, S.; Muller-Vieira, U.; Klein, C.D.; Antes, I.; Lengauer, T.; Hartmann, R.W. Synthesis and evaluation of (Pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem., 2005, 48(5), 1563-75.
111. Ulmschneider, S.; Muller-Vieira, U.; Mitrenga, M.; Hartmann, R.W.; Oberwinkler-Marchais, S.; Klein, C.D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethylene-indanes: potent inhibitors of aldosterone synthase. J. Med. Chem., 2005, 48(6), 1796-805.
112. Saberi, M.R.; Shah, K.; Simons, C. Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: synthesis and inhibition of P450 aromatase. J. Enzyme Inhib. Med. Chem., 2005, 20(2), 135-41.
113. Heidrich, D.D.; Steckelbroeck, S.; Klingmuller, D. Inhibition of human cytochrome P450 aromatase activity by butyltins. Steroids, 2001, 66(10), 763-9.
114. Cooke, G.M. Effect of organotins on human aromatase activity in vitro. Toxicol. Lett., 2002, 126(2), 121-30.
115. Woodhouse, A.J.; Cooke, G.M. Suppression of aromatase activity in vitro by PCBs 28 and 105 and Aroclor 1221. Toxicol. Lett., 2004, 152(1), 91-100.
116. Heneweer, M.; van den Berg, M; de Geest, M.C.; de Jong, P.C.; Bergman, A.; Sanderson, J.T. Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts. Toxicol. Appl. Pharmacol., 2005, 202(1), 50-8.
117. Woo, L.W.; Sutcliffe, O.B.; Bubert, C.; Grasso, A.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V. First dual aromatase-steroid sulfatase inhibitors. J. Med. Chem., 2003, 46(15), 3193-6.
118. Wood, P.M.; Woo, L.W.; Humphreys, A.; Chander, S.K.; Purohit, A.; Reed, M.J.; Potter, B.V. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J. Steroid Biochem. Mol. Biol., 2005, 94(1-3), 123-30.